| Literature DB >> 29529281 |
Fiona A Pearce1,2, Peter C Lanyon2,3, Richard A Watts4, Matthew J Grainge1, Abhishek Abhishek2,3, Richard B Hubbard1.
Abstract
Objectives: We aimed to provide insights into the aetiology of granulomatosis with polyangiitis (GPA), by conducting a large case-control study using a general population-based, prospectively collected database of healthcare records.Entities:
Mesh:
Year: 2018 PMID: 29529281 PMCID: PMC5965083 DOI: 10.1093/rheumatology/kex512
Source DB: PubMed Journal: Rheumatology (Oxford) ISSN: 1462-0324 Impact factor: 7.580
Chronic conditions and their association with developing granulomatosis with polyangiitis
| Diagnosis | Ever before the index date | Main analysis: excluding the last year before index date | ||||||
|---|---|---|---|---|---|---|---|---|
| Cases, | Controls, | Odds ratio (95% CI) | Cases, | Controls, | Odds ratio (95% CI) | |||
| Vascular | ||||||||
| CVD | 74 (9.8) | 707 (9.4) | 1.1 (0.8, 1.4) | 0.7 | 67 (8.9) | 660 (8.8) | 1.0 (0.8, 1.3) | 0.9 |
| Hypertension | 226 (29.9) | 2088 (27.7) | 1.1 (0.9, 1.4) | 0.2 | 205 (27.1) | 1935 (25.6) | 1.1 (0.9, 1.3) | 0.3 |
| Chronic renal impairment | 77 (10.2) | 325 (4.3) | 3.3 (2.5, 4.6) | <0.0001 | 49 (6.5) | 277 (3.7) | 2.1 (1.5, 3.1) | 0.0001 |
| Gout | 38 (5.0) | 284 (3.8) | 1.4 (1.0, 2.0) | 0.09 | 33 (4.4) | 268 (3.6) | 1.2 (0.9, 1.8) | 0.3 |
| Type 2 diabetes | 56 (7.4) | 555 (7.4) | 1.0 (0.8, 1.3) | 0.96 | 45 (5.9) | 496 (6.6) | 0.9 (0.6, 1.2) | 0.5 |
| Autoimmune | ||||||||
| Type 1 diabetes | 12 (1.6) | 48 (0.6) | 2.5 (1.3, 4.8) | 0.009 | 11 (1.5) | 47 (0.6) | 2.4 (1.2, 4.6) | 0.02 |
| Thyroid disease | 83 (11.0) | 453 (6.0) | 2.0 (1.6, 2.6) | <0.0001 | 74 (9.8) | 429 (5.7) | 1.9 (1.4, 2.5) | <0.0001 |
| RA | 40 (5.3) | 80 (1.1) | 5.3 (3.6, 7.8) | <0.0001 | 23 (3.0) | 72 (1.0) | 3.3 (2.0, 5.3) | <0.0001 |
| IBD | 18 (2.4) | 69 (0.9) | 2.6 (1.6, 4.4) | 0.001 | 16 (2.1) | 66 (0.9) | 2.4 (1.4, 4.2) | 0.004 |
| Coeliac disease | 2 (0.3) | 19 (0.3) | 1.1 (0.2, 4.5) | 0.9 | 2 (0.3) | 18 (0.3) | 1.1 (0.3, 4.8) | 0.9 |
| Vitiligo | 1 (0.1) | 15 (0.2) | 0.7 (0.1, 5.1) | 0.7 | 1 (0.1) | 14 (0.2) | 0.7 (0.1, 5.5) | 0.7 |
| Addison’s disease | 0 | 1 (0.01) | ||||||
| Chronic lung disease | ||||||||
| COPD | 41 (5.4) | 273 (3.6) | 1.5 (1.1, 2.2) | 0.02 | 29 (3.8) | 237 (3.2) | 1.2 (0.8, 1.8) | 0.3 |
| Alpha-1 ATD | 0 | 1 (0.01) | ||||||
| Pulmonary fibrosis | 8 (1.1) | 10 (0.1) | 8.0 (3.2, 20.3) | 0.0001 | 4 (0.5) | 7 (0.1) | 5.7 (1.7, 19.5) | 0.01 |
| Bronchiectasis | 20 (2.6) | 34 (0.5) | 6.0 (3.4, 10.6) | <0.0001 | 15 (2.0) | 30 (0.4) | 5.1 (2.7, 9.4) | <0.0001 |
CVD: cardiovascular disease; COPD: chronic obstructive pulmonary disease; alpha-1 ATD: alpha-1 antitrypsin deficiency.
FChronic conditions: association with developing granulomatosis with polyangiitis
Acute, resolving illnesses and their association with developing granulomatosis with polyangiitis
| Years before index date | Cases, | Controls, | Odds ratio (95% CI) | |
|---|---|---|---|---|
| Acute renal impairment | ||||
| 0–1 | 35 (4.6) | 2 (0.03) | 175.0 (42.1, 727.6) | <0.0001 |
| 1–2 | 2 (0.3) | 5 (0.07) | 4.8 (0.9, 26.4) | 0.1 |
| 2–3 | 1 (0.2) | 3 (0.05) | 4.8 (0.4, 53.3) | 0.3 |
| 3–4 | 0 | 3 (0.05) | – | – |
| 4–5 | 5 (0.1) | 0 | – | – |
| Sinus infection | ||||
| 0–1 | 110 (14.5) | 116 (1.5) | 11.2 (8.5, 14.9) | <0.0001 |
| 1–2 | 28 (4.1) | 111 (1.6) | 2.7 (1.8, 4.2) | <0.0001 |
| 2–3 | 20 (3.2) | 86 (1.4) | 2.5 (1.5, 4.1) | 0.001 |
| 3–4 | 16 (2.8) | 86 (1.5) | 1.9 (1.1, 3.2) | 0.04 |
| 4–5 | 12 (2.3) | 86 (1.7) | 1.4 (0.7, 2.6) | 0.3 |
| Upper respiratory tract infection | ||||
| 0–1 | 111 (14.7) | 419 (5.6) | 3.1 (2.4, 3.9) | <0.0001 |
| 1–2 | 64 (9.5) | 397 (5.8) | 1.7 (1.3, 2.3) | 0.0004 |
| 2–3 | 37 (6.0) | 385 (6.2) | 1.0 (0.7, 1.4) | 0.9 |
| 3–4 | 36 (6.4) | 323 (5.7) | 1.1 (0, 8, 1.6) | 0.6 |
| 4–5 | 43 (8.3) | 318 (6.3) | 1.3 (0.9, 1.9) | 0.1 |
| Lower respiratory tract infection | ||||
| 0–1 | 104 (13.7) | 331 (4.4) | 3.7 (2.9, 4.7) | <0.0001 |
| 1–2 | 39 (5.8) | 284 (4.2) | 1.4 (1.0, 2.1) | 0.05 |
| 2–3 | 23 (3.7) | 234 (3.7) | 1.0 (0.6, 1.5) | 0.9 |
| 3–4 | 28 (5.0) | 209 (3.7) | 1.4 (0.9, 2.1) | 0.1 |
| 4–5 | 17 (3.3) | 189 (3.7) | 0.9 (0.5, 1.5) | 0.7 |
| Urinary tract infection | ||||
| 0–1 | 35 (4.6) | 204 (2.7) | 1.8 (1.2, 2.6) | 0.004 |
| 1–2 | 20 (3.0) | 201 (2.9) | 1.0 (0.6, 1.6) | 1.0 |
| 2–3 | 16 (2.6) | 163 (2.6) | 1.0 (0.6, 1.7) | 1.0 |
| 3–4 | 15 (2.7) | 150 (2.7) | 1.0 (0.6, 1.7) | 1.0 |
| 4–5 | 14 (2.7) | 117 (2.3) | 1.1 (0.6, 1.9) | 0.8 |
| Cellulitis | ||||
| 0–1 | 29 (3.8) | 98 (1.3) | 3.1 (2.0, 4.7) | <0.001 |
| 1–2 | 8 (1.2) | 97 (1.4) | 0.9 (0.4, 1.8) | 0.7 |
| 2–3 | 9 (1.5) | 67 (1.1) | 1.4 (0.7, 2.9) | 0.3 |
| 3–4 | 5 (0.9) | 69 (1.2) | 0.7 (0.3, 1.8) | 0.4 |
| 4–5 | 8 (1.5) | 54 (1.1) | 1.4 (0.7, 2.9) | 0.4 |
Smoking and its association with developing granulomatosis with polyangiitis
| Diagnosis | Last record prior to the index date | Last record prior to 1 year before the index date | ||||||
|---|---|---|---|---|---|---|---|---|
| Cases, | Controls, | Odds ratio (95% CI) | Cases, | Controls, | Odds ratio (95% CI) | |||
| Smoking status | ||||||||
| Never | 349 (46.1) | 33505 (46.5) | 1 | 336 (44.4) | 3, 415 (45.3) | 1 | ||
| Former | 172 (22.7) | 1241 (16.5) | 1.5 (1.2, 1.8) | <0.001 | 149 (19.7) | 1, 074 (14.2) | 1.5 (1.2, 1.8) | <0.001 |
| Current | 172 (22.7) | 2052 (27.2) | 0.8 (0.7, 1.0) | 0.037 | 186 (24.6) | 2, 177 (28.9) | 0.8 (0.7, 1.0) | 0.077 |
| Unknown | 64 (8.5) | 744 (9.9) | 0.8 (0.6, 1.1) | 0.12 | 86 (11.4) | 880 (11.7) | 0.9 (0.7, 1.3) | 0.68 |
Medications and their association with developing granulomatosis with polyangiitis
| Drug | Ever before the index date | Excluding the last year before the index date | ||||||
|---|---|---|---|---|---|---|---|---|
| Cases, | Controls, | Odds ratio (95% CI) | Cases, | Controls, | Odds ratio (95% CI) | |||
| Allopurinol | 30 (4.0) | 163 (2.2) | 1.9 (1.3, 2.9) | 0.0032 | 26 (3.4) | 147 (2.0) | 1.8 (1.2, 2.8) | 0.01 |
| Carbimazole | 9 (1.2) | 46 (0.6) | 2.0 (1.0, 4.1) | 0.08 | 8 (1.1) | 43 (0.6) | 1.9 (0.9, 4.1) | 0.13 |
| Levothyroxine | 71 (9.4) | 353 (4.7) | 2.2 (1.7, 2.9) | <0.0001 | 62 (8.2) | 332 (4.4) | 2.0 (1.5, 2.7) | <0.0001 |
| Propylthiouracil | 1 (0.1) | 7 (0.1) | 1.4 (0.2, 11.5) | 0.76 | 1 (0.1) | 5 (0.1) | 2.0 (0.2, 16.8) | 0.57 |
| Hydralazine | 2 (0.3) | 9 (0.1) | 2.3 (0.5, 10.8) | 0.34 | 2 (0.3) | 8 (0.1) | 2.6 (0.5, 12.5) | 0.29 |
| Minocycline | 17 (2.3) | 94 (1.3) | 1.8 (1.1, 3.1) | 0.03 | 14 (1.9) | 90 (1.2) | 1.6 (0.9, 2.8) | 0.1 |
| SSZ | 14 (1.9) | 31 (0.4) | 4.6 (2.4, 8.6) | <0.0001 | 9 (1.2) | 30 (0.4) | 3.0 (1.4, 6.4) | 0.01 |
| Penicillamine | 4 (0.5) | 10 (0.1) | 4.0 (1.3, 12.8) | 0.04 | 4 (0.5) | 10 (0.1) | 4.0 (1.3, 12.8) | 0.04 |
Socio-economic status and its association with developing granulomatosis with polyangiitis
| IMD-10 quintile | Ever before the index date | ||||
|---|---|---|---|---|---|
| Cases, | Controls, | Odds ratio (95% CI)— categorical variable | Odds ratio (95% CI)— continuous variable | ||
| Quintile 1 (most deprived) | 113 (22.2) | 1220 (24.1) | 1 | 1.1 (1.0, 1.2) | 0.02 |
| Quintile 2 | 114 (22.4) | 1303 (25.7) | 0.96 (0.7, 1.3) | ||
| Quintile 3 | 114 (22.4) | 1041 (20.6) | 1.3 (0.9, 1.8) | ||
| Quintile 4 | 102 (20.0) | 854 (16.9) | 1.5 (1.0, 2.1) | ||
| Quintile 5 (least deprived) | 66 (13.0) | 646 (12.8) | 1.3 (0.9, 1.9) | ||
P-value for trend from the likelihood ratio test. IMD-10: Index of Multiple Deprivation 2010.